$LLY

Yuffa Ilya sold $2.9M of LLY

Yuffa Ilya (EVP&Pres, LLY USA&Global Capab) sold 2,500 shares of ELI LILLY & Co (LLY) at $1150.77 ($2.88M total) on 2026-06-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yuffa Ilya
Published Jun 11, 2026, 8:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LLY
Neutral
high confidence
Mentioned
$LLY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LLYNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but 10b5-1 plans generally reduce the informational content versus discretionary sales.

02

Market read

A $2.88M LLY insider sale was disclosed, but it is pre-arranged under 10b5-1, limiting actionable fundamental implications.

03

What to watch

The article provides only the sale details; it does not state whether other insiders or large holders changed positions around the same time.

Relevance 5/10Novelty 6/10Timing: Filed June 11; sale executed June 10

Background

The article is a primary-source SEC Form 4 insider transaction disclosure (open-market sale) for LLY.

Company-level read

Ticker impact

$LLYNeutralHigh confidence
Context

SEC Form 4 shows EVP Yuffa Ilya sold 2,500 shares of LLY for about $2.88M on a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an open-market sale under a pre-arranged 10b5-1 plan, with no accompanying fundamental or regulatory catalyst disclosed.

Market effects

No sector read-through; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal risk management or diversification, which some traders may still fade.

Key entities

  • ELI LILLY & Co

    Company whose shares were sold by an executive under a 10b5-1 plan.

  • Yuffa Ilya

    EVP & President, LLY USA & Global Capabilities; sold 2,500 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LLYHighAI 9/10

Forget Nvidia: Eli Lilly Will Become “the Most Valuable Company in the World,” Says Macro Investor

Eli Lilly (LLY) hit a record high, raising its 2026 revenue forecast to $91-$92B, lifting its market value to $1.1T. Macro investor Jordi Visser predicts Lilly will become the world's most valuable company due to steady healthcare spending and AI investment. Analysts expect Nvidia's (NVDA) earnings per share to quadruple in three years, making Lilly's potential surpass a significant challenge.

$LLYHighAI 9/10

Eli Lilly Just Gained 22% in a Month: Take Profits, or Buy More?

Eli Lilly (LLY) stock rose 22% in October, driven by strong Q3 earnings, higher revenue guidance, and positive clinical trial results for retatrutide. Revenue increased 39% to $24.4B, with Mounjaro and Zepbound contributing significantly. Lilly raised 2026 revenue guidance to $91B-$92B. Goldman Sachs set a $1,413 price target. Novo Nordisk (NVO) faces competition from retatrutide, which outperformed Ozempic in a Phase 3 trial.

$LLYMedAI 8/10

Micron, Samsung and SK hynix shares stumble, but this ETF rallies instead of chip stocks

ETFs focused on global pharmaceutical companies, particularly those in obesity treatment, saw strong returns amid tech and semiconductor stock declines. Eli Lilly reported Q3 revenue of $24.4B, up 38.6% YoY, driven by obesity drugs Mounjaro and Zepbound. Novo Nordisk and other Big Pharma stocks also rose, benefiting from defensive characteristics and upcoming clinical trial announcements.

$LLYHighAI 9/10

Eli Lilly Posts Strong Quarterly Results and Hits Record High Stock Price

Eli Lilly (LLY) reported Q3 revenue of $24.4B, up 39% YoY, driven by GLP-1 drugs Mounjaro and Zepbound. The company raised full-year revenue guidance to $91B-$92B but slightly lowered EPS guidance to $35-$36. Despite strong growth, valuation concerns arise as the stock trades at 45x earnings, with market expectations already priced in.